Key result
Glycemic variability strongly predicts midterm MACE in patients with diabetes and ACS.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in diabetic ACS; leaves open whether targeting variability improves outcomes.
We thank Yang and Hu (1) for their interest in our study (2) on the prognostic value of glycemic variability (GV) in patients with diabetes with acute coronary syndrome (ACS). First, with respect to the comment (1) by Yang and Hu, a Cox proportional hazards regression analysis was carried out additionally including all similar variables as previously studied (2). This multivariable analysis demonstrated that GV still remains the strongest independent predictive factor for midterm major adverse cardiovascular events (MACE) in …
No takes yet. Share an insight, caveat, or question.
Catargi et al. (2019) studied this question. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes and acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: